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SUMMARY
Background
Inﬂammatory bowel diseases (IBD) are chronic relapsing diseases in which
pro-inﬂammatory immune cells and cytokines induce intestinal tissue dam-
age and disability. Mesenchymal stromal cells (MSCs) exert powerful
immunomodulatory effects and stimulate tissue repair.
Aim
To review the current data on mesenchymal stromal cell therapy in IBD.
Method
We searched PubMed and ‘ClinicalTrials.gov’ databases using the terms
‘mesenchymal stromal cells’, ‘mesenchymal stem cell transplantation’, ‘in-
ﬂammatory bowel diseases’, ‘Crohn disease’ and ‘colitis, ulcerative’. Addi-
tional publications were identiﬁed from individual article reference lists.
Results
MSCs include inhibition of Th1/Th17 lymphocytes and recruitment of regu-
latory T lymphocytes, induction of antigen-presenting cells into a regulatory-
like proﬁle, and stimulation of epithelial cell differentiation and proliferation.
More than 200 patients with refractory ﬁstulas have been treated with local
injections of MSCs, resulting in complete response in more than half, and in
overall response in approximately two thirds of patients. In refractory luminal
Crohn’s disease, 49 cases of systemic MSC infusions have been reported,
while trials with autologous MSCs resulted in mitigated responses, studies
using allogeneic MSCs were promising, with around 60% of patients experi-
encing a response and around 40% achieving clinical remission.
Conclusions
Mesenchymal stromal cells might represent a promising therapy for IBD,
especially for Crohn’s disease. There remain many unsolved questions con-
cerning the optimal origin and source of mesenchymal stromal cells, dosage
and modalities of administration. Moreover, mesenchymal stromal cells still
need to prove their effectiveness compared with conventional treatments in
randomised controlled trials.
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INTRODUCTION
Inﬂammatory bowel diseases (IBD) are multifactorial
chronic relapsing diseases involving an abnormal sys-
temic and mucosal immune response against intralumi-
nal antigens, favoured by microbial factors and alteration
of the mucosal barrier.1, 2 A loss of balance between
proinﬂammatory T helper (Th)1/Th17 cells and regula-
tory T lymphocytes (Treg), resulting in the activation of
macrophages and B cells as well as recruitment of circu-
lating leucocytes into the gut, seems to play a key role in
the pathogenesis of IBD.
Mesenchymal stromal cells (MSCs) are multipotent
progenitors that can be isolated from the connective tis-
sues of most organs. In addition to multilineage differen-
tiation and participation in the haematopoietic niche,
they exert powerful immunomodulatory effects, includ-
ing inhibition of proliferation and function of Th1 and
Th17 cells, and promotion of Treg differentiation. More-
over, they display several properties that could make
them interesting for tissue repair: homing to sites of
inﬂammation and tissue damage, differentiation into var-
ious cell types, secretion of soluble factors stimulating
survival and recovery of injured cells and tissues (Fig-
ure 1). The relative importance of these properties for
the efﬁcacy of MSCs on experimental colitis and IBD is
still investigated.
METHODS
Bibliographic searches were performed in PubMed using
the search terms ‘mesenchymal stromal cells’, ‘mesenchy-
mal stem cell transplantation’, ‘inﬂammatory bowel dis-
eases’, ‘Crohn disease’ and ‘colitis, ulcerative’. The
articles were selected based on relevance to this review.
We included additional publications that were identiﬁed
through review of individual article reference lists. A sys-
tematic search was also performed on ‘ClinicalTrials.gov’
using the search terms ‘mesenchymal stromal cells’, ‘in-
ﬂammatory bowel diseases’, ‘Crohn’s disease’ and ‘ulcera-
tive colitis’.
PROPERTIES OF MSCS
Mesenchymal stromal cells can be isolated from bone
marrow, where they support haematopoiesis, but also
from various other tissues such as umbilical cord, umbil-
ical cord blood, placenta, adipose tissue, and seem to
reside in the connective tissues of most organs.3, 4 The
three minimal criteria to deﬁne MSCs are as follows:
(i) adhesion to plastic in standard culture conditions,
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Figure 1 | Potential therapeutic effects of mesenchymal stromal cell in Crohn’s disease.
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(ii) expression of CD73, CD90 and CD105, and lack of
expression of CD34, CD45, CD11b or CD14, CD19 or
CD79a and human leucocyte antigen (HLA)-DR surface
molecules, and (iii) in vitro differentiation into osteo-
blasts, chondroblasts and adipocytes.5 MSCs are consid-
ered as immunoprivileged because they express low
levels of HLA class I molecules and do not express HLA
class II nor co-stimulatory molecules (CD80, CD86 or
CD40) under normal circumstances.6, 7
Immunomodulation
Mesenchymal stromal cells immunomodulatory effects
are pleiotropic and not yet fully understood. They proba-
bly vary among species8 and depend on many parame-
ters such as culture conditions or an inﬂammatory
environment. MSCs were ﬁrst demonstrated to inhibit
T-cell proliferation, whether the lymphocytes are CD4+
or CD8+, naive or memory, and regardless of their func-
tional state,9–13 and independently of the major histo-
compatibility complex, as inhibition is similar using
‘third party’ or autologous MSC.9 The effect of MSCs on
T cells seems to depend on the MSC/T-cell ratio: a
high MSC/T-cell ratio exerts strong inhibitory effects,
whereas a low MSC/T-cell ratio might enhance T-cell
proliferation.14
A key role in the pathogenesis of IBD seems to be
played by enhanced proliferation and defective apoptosis
of immune cells (attributed to an imbalance of the anti-
apoptotic protein Bcl-2 and the proapoptotic protein
Bax),15–17 and it has been demonstrated that Fas-
mediated apoptosis is lower in Crohn’s disease than in
control T cells.18 Whether MSC-inhibited T cells
undergo apoptosis or not has still to be resolved. A
recent study found that systemic infusion of murine
bone marrow MSCs induced T-cell apoptosis through
the Fas ligand-/Fas pathway, and that FASL-/- bone
marrow MSCs were ineffective in a murine model of
dextran sodium sulphate (DSS)-induced colitis.19 How-
ever, in vitro, some authors observed that MSCs did not
induce T-cell apoptosis,11 but rather blocked them in
G0/G1 phase of the cell cycle, in a state of anergy, by
inhibiting cyclin D2 expression,20 or even prevented acti-
vation-induced cell death through downregulation of Fas
receptor and Fas ligand on TCR-activated T cells.21
The pathogenesis of IBD also involves an imbalance
in T-cell subsets, with proinﬂammatory cytokines arising
from Th1 and Th17 cell differentiation in Crohn’s dis-
ease, and Th2 cell differentiation in ulcerative colitis,22–24
whereas Treg is down-regulated.25 Among Treg cells,
CD4+CD25+FoxP3+ T cells play a key role in suppressing
the immune system and maintaining self-tolerance,
through inhibition of proinﬂammatory cytokine produc-
tion, downregulation of costimulatory molecules on anti-
gen presenting cells, and modulation of T-cell
proliferation and differentiation.26 Treg levels are lower
in peripheral blood in IBD patients (both ulcerative coli-
tis and Crohn’s disease) than in healthy controls.25
Recent studies suggest that an important part of MSC-
mediated immunomodulation results from the recruit-
ment of Treg from both naive and memory T cells.27, 28
The mechanisms involve secretion of soluble factors,
such as prostaglandin (PG)-E2, transforming growth fac-
tor (TGF)-b1 or HLA-G, interaction between CCL1 and
CCR8 on T cells, and induction of immature dendritic
cells and monocytes into a regulatory proﬁle.29–32 In
vivo, Treg expansion after MSC infusion has been
observed in several dysimmune diseases.33–35 In several
models of DSS- and trinitrobenzene sulphonate (TNBS)-
induced colitis in mice treated with intravenous or
intraperitoneal injection of human adipose tissue-
derived, umbilical cord or bone marrow MSCs, MSCs
successfully treated colitis (clinical response and
decreased inﬁltration of inﬂammatory cells in the lamina
propria), and authors mostly observed a decreased num-
ber of interferon (IFN)-c-producing Th1 cells and higher
numbers of Treg cells in mesenteric lymph nodes and
colon, lower systemic levels of Th1 and Th17
pro-inﬂammatory cytokines [including tumour necrosis
factor (TNF)-a, IFN-c, interleukin (IL)-6, IL-12, IL-17,
IL-23], and higher systemic levels of the anti-inﬂammatory
cytokine IL-10.36–39 In a murine model of TNBS-induced
colitis, MSCs co-localised with CD11b+ cells in the
spleen, and these cells were essential to the expansion of
Treg cells in draining mesenteric lymph nodes.40
Antigen presenting cells, such as dendritic cells and
macrophages, are also involved in IBD pathogenesis,
through generation and polarisation of T-cell
responses.41 In vitro, MSCs inhibit dendritic cell matura-
tion (through a down-regulation of cyclin D2 and
p27Kip1 expression, resulting in a blockade in G0/G1
phase of the cell cycle), impair their antigen-presenting
and migration functions, modulate their secretion of
cytokines (increased IL-10 and decreased IL-12 produc-
tion), and induce them to differentiate into regulatory
dendritic cells (through the Notch signalling path-
way).42–46 These effects have been conﬁrmed in vivo in
murine models.47 MSCs also interact with macrophages,
inducing them into a regulatory-like proﬁle48 and
increasing their production of IL-10.49 In DSS and
TNBS-induced mouse colitis, intraperitoneal injection of
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murine bone marrow macrophages cultured with adipose
tissue-derived MSCs successfully treated colitis and sep-
sis. In vitro, these macrophages displayed a regulatory
phenotype [high arginase activity, increased expression
of IL-10 and inducible NO synthase (iNOS), lower pro-
duction of TNFa and IL-12] and showed potent
immunosuppressive activity on splenocytes.50
Effects of MSCs on B cells and natural killer cells are
still debated and may depend on environmental signals
and MSC/effector cell ratio. Most studies found that
MSCs inhibit B-cell activation, proliferation, chemotaxis
and IgG secretion, and it was recently demonstrated that
MSCs could increase IL-10 producing CD5+ regulatory B
cells (Bregs),51–54 but one study found that MSC pro-
moted proliferation and differentiation of naive B cells
into immunoglobulin-secreting cells.55 Similarly, MSCs
seem to inhibit natural killer cell proliferation and their
secretion of pro-inﬂammatory cytokines, but whether
they do or do not decrease their cytotoxic activity is
controversial.30, 56–59
Mechanisms of MSC-mediated immunomodulation
in vitro imply direct cell contacts and secretion of soluble
factors, mostly PGE2, indoleamine 2,3 dioxygenase
(IDO), nitric oxide (NO) and HLA-G.29, 30, 60–62 In DSS
or TNBS-induced mouse colitis, NOD2-activated human
umbilical cord MSCs reduced the severity of colitis
through the secretion of PGE-2, and this was associated
with increased Treg colonic inﬁltration and increased IL-
10 levels.63 IL-10 is probably not secreted directly by
MSCs but participate to their immunosuppressive effect,
as this effect is decreased by IL-10 blockade.35 The tran-
scription factor Aire might also be involved in MSC
immunomodulation through repression of early T-cell
activation factor 1 (Eta-1), as it was required for their
efﬁcacy in a model of chronic colitis (induced by transfer
of CD4+ CD45RBhi T cells in Rag/ mice), but it did
not control MSC suppression of T-cell proliferation
in vitro.64
As mentioned above, immunomodulatory effects of
MSCs depend on the inﬂammatory environment. Many
factors have been shown to modulate MSC-mediated
immunosuppression, such as toll-like receptors
(TLRs),65–67 IFN-c, TNF-a and IL-1b.68 IFN-c pre-
treated human bone marrow MSCs or IFN-c-transfected
umbilical cord MSCs were more potent to inhibit
peripheral blood mononuclear cell or T-lymphocyte pro-
liferation in vitro, and were superior to resting MSCs to
treat DSS- and/or TNBS-induced colitis. This was associ-
ated with an increased expression of MHC II, IDO and
iNOS, lower expression of several colonic inﬂammatory
cytokines (such as IL-6, IL-1b, TNF-a, IFN-c or IL-
17A). An increased percentage of Treg and Th2 cells
and a decreased percentage of Th1 and Th17 cells have
also been observed both in mesenteric lymph nodes and
in spleen of mice treated with IFN-c primed MSC.69, 70
IL-1b-priming of human umbilical cord MSCs increases
their expression of COX-2, IL-6 and IL-8 mRNA and
improves their ability to migrate into the spleen, mesen-
teric lymph nodes and colon (through upregulation of
CXCR4 expression), and to attenuate DSS-induced mur-
ine colitis (associated with increased numbers of peri-
toneal M2 macrophages and splenic or mesenteric lymph
node Treg).71
Tissue regeneration
Homing. Mesenchymal stromal cells have demonstrated
their ability to migrate selectively into various sites of tis-
sue injury and inﬂammation,72–74 including inﬂamed
zones of the intestine (lamina propria, muscular layer
and submucosa) and mesenteric lymph nodes in murine
models of colitis, whatever their origin or their route of
administration.37–39, 74–76 We still lack information on
the persistence of MSCs in these tissues since, in most
studies, MSC tracking analyses were only performed dur-
ing the ﬁrst week after MSC injection, and MSCs were
detected in inﬂamed zones of the intestine every time,74–76
except in one study where MSCs were detected until day
5, but not on day 737; however, MSCs were still found in
inﬂamed colonic tissues 15 days after injection in the
only study in which tracking analyses were performed
until that time point.38 Signals modulating MSC migra-
tion include growth factors [vascular endothelial growth
factor (VEGF), platelet-derived growth factor, etc.],77, 78
and interaction between chemokines and various C-C
chemokine receptors.35 Moreover, MSCs express different
adhesion molecules involved in tissue transmigration
[intercellular adhesion molecule (ICAM), vascular cell
adhesion protein (VCAM), etc.] and integrins.36 Activa-
tion by IFN-c or IL-1b and targeting via VCAM
antibody-coating may improve the homing of MSCs into
mesenteric lymph nodes and colon, and therefore their
efﬁcacy on murine colitis.69, 70, 79
Differentiation and tissue repair stimulation. In response
to inﬂammation or tissue injury, MSCs are able to differ-
entiate into various cells of the mesenchymal lineage and
to engraft into many tissues,80–82 where they promote
tissue repair.83–89 In a model of DSS-induced rat colitis,
intravenously administered rat MSCs migrated to the
lamina propria of the injured colon, where they
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upregulated their expression of a-smooth muscle actin
(a-SMA), and were able to heal epithelial injuries. How-
ever, tissue repair properties of MSCs are not so much
due to their differentiation capacities, but rather to their
ability to stimulate survival and recovery of local tissues,
through stimulation of angiogenesis and inhibition of
apoptosis and ﬁbrosis in injured tissues.90–92 In mice suf-
fering from TNBS-induced colitis, intravenous injection
of murine bone marrow MSC increased proliferation of
intestinal epithelial cells and differentiation of intestinal
stem cells, as attested by the increased expression of
Ki67 and leucine-rich repeat-containing G-protein-
coupled receptor 5 (LGR5) in damaged tissues.75 In a rat
model of TNBS-induced colitis, topically implanted rat
bone marrow MSCs were detectable in submucosal layers
at days 3 and 6 post-implantation and successfully
healed mucosal injuries. A small proportion of MSCs
was positive for a-SMA and desmin, indicating differen-
tiation into myoﬁbroblasts, but most rather expressed
VEGF and TGF-b1, two important growth factors in
gastrointestinal wound healing.93 In DSS-induced colitis
in rats, intravenously administered allogeneic MSCs
reduced epithelial injury and restored expression of clau-
din-2, claudin-12 and claudin-15, proteins constituting
tight junctions and known to have a major role in the
paracellular permeability of the epithelial barrier.94
MSC THERAPY IN IBD
Autologous and allogeneic MSCs have been evaluated in
human trials, in two different modalities: local injection
of MSCs to treat ﬁstulising Crohn’s disease and intra-
venous injection of MSCs to treat luminal Crohn’s dis-
ease or ulcerative colitis.
MSC therapy for ﬁstulising Crohn’s disease
Management of ﬁstulas associated with Crohn’s disease
has remained a challenging problem since many such ﬁs-
tulas do not respond to available treatments, including
most effective molecules such as anti-TNF. Surgical
treatments (i.e. endoanal advancement ﬂap) can cure
some ﬁstulas but anal incontinence and recurrence are
not rare. Local administration of autologous or allogeneic
adipose tissue-derived or bone marrow MSCs have sug-
gested some efﬁcacy and reassuring safety in several
phase I or II trial. Results were uniformly positive what-
ever the origin and despite variation in dose and schema
of injection, and two randomised controlled trials
demonstrated the superiority of autologous and allo-
geneic MSCs over placebo (Table 1). To date, more than
200 patients with refractory ﬁstulas associated with
Crohn’s disease have been treated with local injections of
MSCs, resulting in complete response in more than half
(sustained for at least 24 weeks for around 75% of them)
and in overall response in approximately two thirds of
patients. Several phase I–III clinical trials aimed at fur-
ther exploring local injection of autologous or allogeneic
adipose tissue-derived or bone marrow MSCs in ﬁstulis-
ing Crohn’s disease are currently ongoing (Table 2).
Autologous MSC therapy for ﬁstulising Crohn’s
disease. In a phase I study, four patients suffering from
one or more refractory complex Crohn’s ﬁstulas were
treated with a single intraﬁstular injection of 3–30 9 106
autologous adipose tissue-derived MSCs. The authors
observed healing of 6/8 ﬁstulas at 8 weeks, and partial
closure with decreased drainage in 2/8 ﬁstulas. There
were no adverse effects after 12- to 22-month follow-
up.95 Then, in a phase IIb trial, 49 patients with complex
perianal ﬁstulas were randomly assigned to treatment
with intralesional injection of ﬁbrin glue or ﬁbrin glue
plus 20 million adipose tissue-derived MSCs, followed by
a second double dose of adipose tissue-derived MSCs if
ﬁstula healing was not obtained at 8 weeks. Fistula heal-
ing occurred in 17/24 patients receiving adipose tissue-
derived MSCs (11 patients healed after the ﬁrst injection
and 6 patients after a second injection) compared with
4/25 in the control group (RR 4.43, P < 0.001). Improve-
ment in quality of life was signiﬁcantly greater in the
treated group compared with the control group, even in
patients whose ﬁstula did not heal.96 After a mean fol-
low-up of 40 months, 7/12 patients treated with adipose
tissue-derived MSCs remained free of recurrence (2/3 in
the control group). The incidence of perianal sepsis was
lower in the treated group (P = 0.04). No adverse effect
was related to adipose tissue-derived MSCs, conﬁrming
their very good safety and tolerability proﬁle.97
Another group performed a small dose escalation
phase I study, in which 10 patients with a perianal ﬁstula
associated with Crohn’s disease were treated with
intraﬁstular injection of autologous adipose tissue-
derived MSCs at a dose of 1 9 107, 2 9 107 or 4 9 107
cells/mL in proportion to the size of the ﬁstula (total of
3–40 9 107 cells). After 8 weeks, complete healing was
observed in 3/10 patients (2 of the 2 9 107 group and 1
of the 4 9 107 group), while partial closure with no
drainage was observed in all other patients. These results
were sustained after 8 months and no adverse effect was
observed.98 Then, the same group led a phase II trial,
with 43 patients with perianal ﬁstulae receiving a ﬁrst
intraﬁstular injection of adipose tissue-derived MSCs
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Table 1 | Completed trials – intraﬁstular injection(s) of MSCs for ﬁstulising Crohn’s disease




I 4 3–30 9 106 MSCs Clinical evaluation at
week 8
6/8 ﬁstulas healed, 2/8 improved95
Adipose
tissue
IIb 49 20 9 106 MSCs with
ﬁbrin glue or placebo
(ﬁbrin glue alone);
repeated with






(i) Fistula healing in 17/24 patients, sustained
in 7/12 patients (vs. 4/25 and 2/3 in control
group)
(ii) Improved quality of life
(iii) Lower incidence of perianal sepsis96, 97
Adipose
tissue
I 10 10, 20 or 40 9 106
MSCs/ml in
proportion to the




Sustained complete healing in 3/7 patients,
partial closure in all other patients98
Adipose
tissue
II 43 30–60 9 106 MSCs/
cm, with ﬁbrin glue,
repeated with






Complete ﬁstula healing in 27/42 patients
(sustained in 23/26 patients) and incomplete
closure in 6/42 patients99
Bone
marrow
I 10 2–5 monthly
injections of
15–30 9 106 MSCs
Clinical, surgical and MRI
evaluation at the time
of each treatment and
3, 6 and 12 months
after the last procedure;
1-year follow-up
(i) Complete closure of ﬁstula tract in 7/10
patients, incomplete closure in 3/10
(ii) Sustained reduction of CDAI and PDAI in
all patients
(iii) Rectal mucosal healing in 7/7 patients.
Increase in the percentage of circulating and
mucosal Treg (at 12 months)100
(iv) Increase in the percentage of circulating




I/IIa 24 20 9 106 MSCs, then




evaluation at weeks 12
and 24; 24-week
follow-up
(i) At week 12, improvement of ≥1 ﬁstula in
12/20 patients (9/13 at week 24) and complete
closure in 8/21 patients (9/16 at week 24)
(ii) Decreased MRI Score of Severity at week
12 and PDAI at week 24; no effect on CDAI101
Adipose
tissue
III 212 120 9 106 MSCs to
all ﬁstula tract or
placebo
Clinical evaluation at
weeks 6, 12, 18 and 24
and combined clinical
and MRI evaluation at
week 24
(i) Fistula closure in 53/107 patients in the
MSC group (vs. 36/105 in the placebo group;
P = 0.024), obtained in a signiﬁcantly shorter
time in the MSC group (6.7 vs. 14.6 weeks)
(ii) Signiﬁcantly greater improvement in PDAI
in the MSC group vs. placebo at week 6, but
not at week 24. Treatment-related adverse
events in 18/103 patients in the MSC group vs.
30/103 in the placebo group102
Bone
marrow
IIa 21 10, 30 or 90 9 106
MSCs, or placebo
Clinical evaluation at
weeks 6, 12 and 24;
endoscopic and MRI
evaluation at week 12
(i) Healing in 8/15 patients (12/23 individual
ﬁstulas) in MSC groups at week 6 and 7/15
patients (11/23 ﬁstulas) at week 12, vs. 1/6 and
2/6 patients (2/9 and 3/9 ﬁstulas) in the
placebo group, sustained at week 24
(ii) Better results in the 10 9 106 and
30 9 106 MSC groups compared to the
90 9 106 MSC group103
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with a number of cells proportionate to the size of the
ﬁstula (3 9 107 or 6 9 107 cells per 1 cm of ﬁstula
length, depending on whether the diameter was less or
more than 1 cm, average number of 15.8 9 107 cells),
followed by a second injection of 1.5 times more cells
(average number of 19.1 9 107 cells) if ﬁstula closure
was not complete at 8 weeks. Moreover, the ﬁstula tract
was ﬁlled with a mixture of adipose tissue-derived MSCs
and ﬁbrin glue. Complete ﬁstula healing was observed in
27/42 patients by 8 weeks after the ﬁnal adipose tissue-
derived MSC injection and sustained after 1 year in 23/
26 patients. Six other patients had an incomplete closure,
with 5 of them achieving a closure by more than 50% of
ﬁstula tract with a decrease in drainage of more than
50%. No adverse event related to adipose tissue-derived
MSCs was observed.99
Autologous bone marrow MSCs were evaluated in
only one trial, with 10 patients suffering from ﬁstulising
Crohn’s disease refractory to all previous medical treat-
ments (including anti-TNF therapy) or surgery. They
received intraﬁstular injections of 15–30 9 106 MSC
every 4 weeks until an improvement was obtained or
when autologous MSCs were no longer available (2–5
injections). Sustained complete closure of ﬁstula tract
was observed in 7/10 patients and incomplete closure in
3/10 patients, with images of regenerative tissue without
ﬁbrotic tissue obtained at MRI. A signiﬁcant reduction
of Crohn’s disease activity index (CDAI) (P < 0.001)
and PDAI (P < 0.001) was observed in all patients, with
remission (CDAI ≤ 150, PDAI ≤ 8) obtained usually
after the second procedure. Rectal mucosal healing,
assessed by lower endoscopic examination at the end of
the follow-up period, was demonstrated in 7/7 patients.
Interestingly, there was a signiﬁcant increase in the per-
centage of circulating CD4+CD25brightFoxP3+ regulatory
T cells (as early as after the second injection, and stable
at 12 months) (P < 0.01) and mucosal FoxP3+ regulatory
T cells in the inﬂamed areas (at 12 months)
(P < 0.0001). There was no adverse event during the
procedure nor during the 12-month follow-up period.100
Allogeneic MSC therapy for ﬁstulising Crohn’s
disease. In a single-arm, multicentre phase I/IIa clinical
trial, 24 patients suffering from complex perianal ﬁstula
associated with non-active luminal Crohn’s disease
received an intraﬁstular treatment with 20 million allo-
geneic adipose tissue-derived MSCs, followed by a second
administration of 40 million adipose tissue-derived MSCs
if ﬁstula closure was incomplete at week 12. Improvement
of ≥1 ﬁstulae was observed in 12/20 patients at week 12
and 9/13 at week 24, while complete closure (assessed by
clinical examination) occurred in 8/21 patients at week 12
and 9/16 at week 24. There were statistically signiﬁcant
decreases of MRI Score of Severity (MSS) at week 12 and
of PDAI (by more than 37% compared to baseline;
P < 0.01), while no effect was observed on the CDAI.
After a 6-month follow-up, the safety proﬁle was accept-
able with a low number of serious adverse events (includ-
ing anal abscess in three patients and uterine leiomyoma
in one patient).101 Finally, the ﬁrst results of a recent
phase III, double-blind, randomised trial have been pub-
lished: 212 patients with refractory complex active peri-
anal ﬁstulas associated with non-active luminal Crohn’s
disease were treated with surgical closure of the internal
opening of the ﬁstula(s) followed by a single injection of
either 120 9 106 adipose tissue-derived MSCs or placebo
into the tissue adjacent to all ﬁstula tracts and internal
openings, in addition to their current treatment. After
24 weeks, there was a signiﬁcantly greater proportion of
patients achieving ﬁstula closure (assessed by both clinical
and MRI evaluation) in the MSC group compared with
placebo (53/107 vs. 36/105, P = 0.024, RR 1.42), with a
Table 2 | Ongoing protocols – Intraﬁstular injection(s) of MSC for ﬁstulising Crohn’s disease
NCT number Localisation Phase Origin Schema Status
Autologous MSC therapy
NCT 01874015 Royan Institute, Iran I Bone marrow 4 monthly injections Recruiting
NCT 01915927 Mayo Clinic, USA I Adipose tissue 1 ﬁstula plug coated with 20 9 106 MSCs Recruiting
NCT 02403232 Papa Giovanni XXIII
Hospital, Italy
II Adipose tissue 1 injection Recruiting
Allogeneic MSC therapy
NCT 02677350 University of Miami
Miller School of
Medicine, USA
I Bone marrow 1 injection of 20 9 107 MSCs, repeated
maximum 4 times at 4-week intervals
Not yet
recruiting
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signiﬁcantly shorter time to obtain clinical remission (clo-
sure of all treated external openings) in the MSC group
(6.7 vs. 14.6 weeks). Compared with placebo, MSC therapy
was associated with a signiﬁcantly greater improvement in
PDAI at week 6, but not at week 24. MSC injection was
well tolerated (17.5% patients experiencing treatment-
related adverse events vs. 29.4% in the placebo group, the
most common being anal abscess and proctalgia).102
The efﬁcacy of allogeneic bone marrow MSCs was also
assessed in a phase IIa trial, in which 21 patients suffer-
ing from refractory perianal ﬁstulising Crohn’s disease
were randomly assigned to groups given injections of
1 9 107, 3 9 107 or 9 9 107 MSCs, or placebo (solution
with no cells), into the wall of the ﬁstula, around the
internal opening. Healing was observed in 8/15 patients
in the MSC groups at week 6 and 7/15 patients at week
12 vs. 1/6 and 2/6 patients in the placebo group at the
same time points. These effects were maintained until
week 24. Overall, better results were obtained in the
1 9 107 and 3 9 107 MSC groups compared with the
9 9 107 MSC group.103
MSC therapy for luminal IBD
Intravenous injection of autologous MSCs has only been
evaluated in two small trials, with underwhelming
results, while intravenous injections of allogeneic MSCs
have been more successfully performed in several clinical
studies (Table 3). Thirty-one cases of refractory luminal
Crohn’s disease or ulcerative colitis treated with systemic
infusions of allogeneic MSCs have been reported, and
the results were promising, with around 60% of patients
experiencing a response and around 40% achieving clini-
cal remission, but MSCs still have to prove their superi-
ority to placebo in this setting. Many clinical trials are
also currently including patients suffering from Crohn’s
disease or ulcerative colitis (Table 4), using mostly allo-
geneic bone marrow, adipose tissue-derived or umbilical
cord MSCs, but also, in one trial, autologous MSCs.
Autologous MSC therapy for luminal IBD. Intravenous
injection of autologous bone marrow MSCs has been
evaluated in two small phase I trials. In the ﬁrst trial,
nine patients with moderate-to-severe refractory Crohn’s
disease (CDAI between 220 and 450, refractory to medi-
cal treatments including anti-TNF therapy) received two
intravenous injections of 1–2 9 106 cells/kg, 7 days
apart. The authors observed a clinical response (decrease
in CDAI by ≥70 points) in 3/9 patients but no clinical
remission (CDAI <150) and even signiﬁcant worsening
of the disease in 4/9 patients, requiring surgery or rescue
medication within 14 weeks after treatment, despite a
trend for lower CD4+ T-cell and higher CD4+CD127+
Treg numbers in the inﬂamed mucosa.104 In the second
trial, 12 patients with moderate-to-severe refractory
Crohn’s disease (CDAI >220, refractory to medical treat-
ments including anti-TNF therapy) received one infusion
of 1, 5 or 10 9 106 MSCs/kg. Clinical response (decrease
in CDAI by ≥100 points) was observed in 5/11 patients
2 weeks after infusion (two patients in the 2 9 106
group, one in the 5 9 106 group and two in the
10 9 106 group), but 5/11 patients experienced a wors-
ening of Crohn’s disease during the 9-week follow-up
(two patients in the 2 9 106 group, one in the 5 9 106
group and two in the 10 9 106 group). Two serious
adverse events were considered possibly related to MSC
therapy: severe Crohn’s colitis and appendicitis 9 days
after infusion in one patient, and Clostridium difﬁcile
colitis 30 days after infusion in another patient.105
Allogeneic MSC therapy for luminal IBD. In a phase II
pilot study, nine patients with refractory moderate-to-
severe Crohn’s disease (CDAI ≥220, unsuccessfully trea-
ted with steroids and immunomodulators) received an
intravenous injection of 2 9 106 or 8 9 106 bone mar-
row MSCs/kg. After 28 days, CDAI was decreased in all
patients (mean decrease of 105, P = 0.004), with clinical
response (reduction in CDAI ≥100) in 3/9 patients,
among which one patient was even in clinical remission
(CDAI <150). All patients reported an increased quality
of life by day 28 (P = 0.008). No infusion reaction was
observed, and ﬁve patients experienced mild to moderate
adverse events.106 Another group led a phase I clinical
trial in which seven patients with IBD (four patients
with Crohn’s disease and three with ulcerative colitis)
received one intravenous infusion of 1 9 106/kg allo-
geneic MSCs (bone marrow MSCs from healthy family
members or umbilical cord MSCs), while continuing
their treatment with steroids and/or immunosuppressors.
After 3 months, a signiﬁcant reduction in CDAI/CAI
was observed in all patients, with remission achieved in
5/7 patients (2/4 with Crohn’s disease and 3/3 with
ulcerative colitis) and endoscopic improvement in 3/4
patients (2/2 with Crohn’s disease and 1/2 with ulcera-
tive colitis). Remission lasted for more than 2 years in
two patients, while two other patients relapsed at 6 and
7 months. One patient with Crohn’s disease had a signif-
icant reduction in ﬁstula size and drainage. Histological
analysis of biopsy specimens showed a reduction of the
extent of the inﬂamed area and of the lymphocytic inﬁl-
tration in the lamina propria. No serious adverse effect
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was reported, after a mean follow-up of 19 months
(range 6–32 months).107 Finally, in a phase II study, 16
patients with refractory active luminal Crohn’s disease
(CDAI >250, refractory to inﬂiximab or adalimumab)
received weekly intravenous infusions of 2 9 106/kg
allogeneic bone marrow MSCs for 4 weeks. After
42 days, the authors observed a reduction of the mean
CDAI scores after each MSC infusion and improved
mean quality of life scores. Clinical response occurred in
12/15 patients, clinical remission in 8/15 patients and
endoscopic improvement in 7/15 patients. Normalisation
of CRP levels was observed in 2/7 patients.108
Issues to be resolved
Sources and origins of MSCs. Most of the published
human trials on ﬁstulising Crohn’s disease were
performed with adipose tissue-derived MSCs95–98, 101, 102;
only two studies used bone marrow MSCs.100, 103 On
the contrary, only bone marrow or umbilical cord
MSCs have been used as systemic therapy to treat lumi-
nal CD.104–108 The greatest advantage of adipose tissue-
derived MSCs is their accessibility in large number and
using minimally invasive procedures. More and more
data are available on the differences between bone mar-
row, adipose tissue-derived and umbilical cord MSCs,
including on their immunomodulatory properties. Sev-
eral studies suggest that adipose tissue-derived and
umbilical cord MSCs might be superior to bone mar-
row MSCs in suppressing immune responses
in vitro.109–113 Therefore, studies comparing their efﬁ-
cacy in vivo will have to be performed in order to
answer this question.
Table 3 | Completed trials – intravenous infusion(s) of MSC for luminal Crohn’s disease or ulcerative colitis
Origin Phase N Schema Evaluation Response
Autologous MSC therapy
Bone marrow I 9 2 injections of






(i) Clinical response in 3 patients, worsening of
the disease in 4 patients
(ii) Endoscopic improvement in 2 patients104
Bone marrow I 12 1 injection of 2, 5 or
10 9 106 MSCs/kg
Clinical evaluation
at week 2; 9-week
follow-up
(i) Clinical response (decrease in CDAI >100)
in 5 patients (2 patients in the 2 9 106 group, 1 in
the 5 9 106 group and 2 in the 10 9 106 group)
(ii) Worsening of Crohn’s disease in 5 patients
during follow-up (2 patients in the 2 9 106 group,
2 in the 5 9 106 group and 1 in the
10 9 106 group)
(iii) Serious adverse events possibly related to
MSC therapy in 2 patients (severe Crohn’s colitis
and appendicitis; and Clostridium Difﬁcile colitis)105
Allogeneic MSC therapy
Bone marrow II 9 2 or 8 9 106 MSCs/kg Clinical evaluation
at day 28
(i) Decrease in CDAI in all patients, with
clinical response in 3/9 patients and clinical
remission in 1 patient




I 7* 1 9 106 MSCs/kg Clinical evaluation
at month 3;
6-month follow-up
(i) Signiﬁcant reduction in CDAI/CAI in all
patients, with remission in 5/7 patients
(ii) Endoscopic improvement in 3/7 patients
(iii) Reduction in ﬁstula size and drainage in
1 patient
(iv) Reduction in extent of the inﬂamed area and
in lymphocytic inﬁltration in mucosa propria107
Bone marrow II 15 4 weekly infusions of




42 days after the
ﬁrst injection
(i) Clinical response in 12/15 patients, clinical
remission in 8/15 patients
(ii) Endoscopic improvement in 7/15 patients
(iii) Improved quality of life108
(iv) Normalisation of CRP levels in 2/7 patients
* Four patients with Crohn’s disease and three patients with ulcerative colitis.
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Both autologous and allogeneic MSCs have demon-
strated some efﬁcacy in ﬁstulising Crohn’s disease, while
allogeneic MSCs have shown more promising results
than autologous MSCs in luminal Crohn’s disease. The
use of autologous MSCs is debated since MSCs could be
altered in patients with Crohn’s disease. Indeed, in other
auto-immune diseases, such as SLE, MSCs have lower
proliferation rates,114 and the use of autologous MSCs in
SLE has led to disappointing results. However, when
compared to MSCs from healthy donors, MSCs from
patients with Crohn’s disease have similar growth poten-
tial and T-cell suppression properties in vitro.104, 115
Adipose tissue-derived MSCs from donors with Crohn’s
disease have also demonstrated their therapeutic effect
on DSS-induced colitis in mice.115 Nevertheless, allo-
geneic MSCs represent a more consistent source of cells
and have the advantage that they can be used regardless
of the centre’s expertise generating autologous MSCs.
Dosage and modalities of administration. Concerning
ﬁstulising Crohn’s disease, local injection of MSCs is
indubitably the most interesting route of administration.
In most recent trials,102 the injection was performed in
the ﬁstula wall itself and was associated to a surgical
closure of the inner opening of the ﬁstula. These details
of local injection may have an important impact on the
observed results and should be further clariﬁed. On the
contrary, in luminal Crohn’s disease, the extent and dis-
semination of lesions impose systemic administration.
Both intravenous and intraperitoneal injections are efﬁ-
cient in mice, except in one study with cryopreserved
MSCs, where only the intraperitoneal administration
allowed migration to the inﬂamed colon and attenuation
of colitis.76 In patients, intravenous injection is easy,
minimally invasive and safe. However, it is known that
many MSCs are stopped in the lungs, and the proportion
of MSCs reaching the inﬂamed intestine has not been
evaluated. Infusion of MSCs via the mesenteric artery
may increase the amount of MSCs reaching the inﬂamed
organ and has been successfully performed in one
patient without any complication.116 However, this route
of administration is clearly more invasive, and its interest
appears minimal as intravenous infusion seems efﬁcient.
Trials showing efﬁcacy of intravenous MSCs have used
different doses and schedules of administration, with a
total dose varying from 1 to 10 million MSCs per kilo
body weight. In two small studies, authors observed simi-
lar results in the different dose groups.105, 106 Promising
Table 4 | Ongoing protocols – allogeneic MSC therapy for luminal Crohn’s disease and/or ulcerative colitis
Disease Localisation Phase Origin Schema




















4 injections over 2 weeks, of
either 600 9 106 or
1.2 9 109 MSCs, or placebo
Active, not
recruiting






1 IV injection of either 0.5 or
1 9 108 MSCs
Unknown




1 IV injection of 2 9 107
MSCs, followed 1 week later
by 1 injection of 1 9 107
MSCs in the mesenteric artery
Unknown








injections of 60 9 106 cells
in the affected colonic
submucosa
Unknown






3 weekly IV infusions of either
1 9 106 MSCs/kg or placebo
Recruiting









8 weekly IV infusions of
1 9 106 cells/kg
Recruiting
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results have been obtained whether patients received a
single injection of MSCs106, 107 or repeated injections,108
but no long-term follow-up data are available. In ﬁstulis-
ing Crohn’s disease, the number of injected MSCs varied
depending on the trial, but the injection schedule was
more constant: most authors chose to realise a single
injection of MSCs, sometimes repeated after 6–8 weeks
(with a similar or higher dose) only if a complete clo-
sure of the ﬁstula was not obtained, and in most cases,
ﬁstula improvement or healing was sustained up to
1 year.95–98, 101, 103 Results were uniformly positive
regardless of the number of MSCs; however, in a recent
phase II trial, better results were obtained in the groups
receiving 1 9 107 or 3 9 107 MSCs compared with the
group receiving 9 9 107 MSCs.103 Therefore, the optimal
amount of MSCs and the best schedule of treatment are
yet to be determined, and dose escalation trials will have
to be performed to resolve this issue.
Ex vivo strategies to modify MSCs. As mentioned
above, IFN-c-primed-MSCs have demonstrated more
potent immunosuppressive properties in vitro and were
superior to treat murine colitis.69, 70 These ﬁndings led
to the assumption that the in vivo efﬁcacy of resting
MSCs relies on their activation by pro-inﬂammatory
cytokines when administered after the onset of inﬂam-
mation. This is corroborated by the demonstration that
adipose tissue-derived MSCs increased survival rate,
ameliorated body weight loss and improved colon
inﬂammation in DSS-induced colitis when injected at
day 2, but were ineffective when injected 1 day or
1 week before colitis induction.36 Similar results have
been obtained in models of other inﬂammatory condi-
tions, such as graft-versus-host disease117 and delayed-
type hypersensitivity.68 However, there is a recent case
report of failure of IFN-c pre-treated MSCs to treat a
child with refractory Crohn’s disease.118
Conventional culture methods involve the use of foetal
bovine serum as a source of growth factors, but some
concerns have been raised about infection transmission
and immunogenicity. Indeed, foetal bovine serum pro-
teins are internalised by MSCs, and anti-foetal bovine
serum antibodies have been detected in the serum of
patients treated with MSCs, which might trigger
immunological reactions and lysis of MSCs in vivo.119
Human platelet lysate is a human alternative that has
gained clinical interest due to its properties to accelerate
wound healing; importantly, human cord blood-derived
platelet lysate co-injected with adipose tissue-derived
MSCs isolated from Crohn’s disease patients enhanced
their therapeutic activity in a mouse model of
DSS-induced colitis.120 In vitro, human platelet lysate is
superior to foetal bovine serum for stimulation of MSC
proliferation (particularly adipose tissue-derived MSCs),
without impairing their immunosuppressive properties,
but effects on chemokine receptor and integrin expres-
sion have still to be clariﬁed.121, 122 In most experiments
on murine colitis and human Crohn’s disease, MSCs
were cultivated with foetal bovine serum; there were only
two trials with MSCs expanded with human platelet
lysate, resulting in similar results than in studies using
MSCs expanded with foetal bovine serum.100, 105 Inter-
estingly, in other conditions such as graft-versus-host
disease (GVHD), recent meta-analyses found no differ-
ence in the outcome of patients treated with systemic
infusions of MSCs cultivated with human platelet lysate
or foetal bovine serum.123, 124
As mentioned above, MSC efﬁcacy in tissue repair is
conditioned by their ability to home into sites of inﬂam-
mation, where they secrete humoral factors such as
cytokines that improve the function of local cells. The
fate of MSCs after local or systemic administration is still
debated, and some data might be biased by the detection
limits of the methods used. For instance, Devine et al.
studied the engraftment of GFP-marked autologous or
allogeneic MSCs in nonhuman primates following total
body irradiation; in a ﬁrst experiment, MSCs were
detected (by semi-quantitative polymerase chain reac-
tion) only in bone marrow biopsies in all ﬁve recipi-
ents,125 while in a second experiment, they were able to
detect (by reverse transcriptase polymerase chain reac-
tion) a prolonged (9–21 months) engraftment in many
organs and tissues.72 In humans, MSCs do not seem to
engraft durably, with MSC donor DNA detection
decreasing in a time-dependent manner.126 In order to
enhance long-term beneﬁcial effects of MSCs, attempts
are being made to increase this engraftment. In several
animal models of myocardial infarction, pulmonary
ﬁbrosis or diabetic erectile dysfunction, pre-conditioning
of MSCs in hypoxic conditions or with antioxidants
molecules (such as high-density lipoproteins, curcumin,
atorvastatin, melatonin and several others) increased
their expression of chemokines such as CXCR4 and their
survival capacities, resulting in enhanced homing and
engraftment, and ultimately in better efﬁcacy.127 These
strategies should be studied and implemented in the set-
ting of IBD (either systemic infusion of MSCs for lumi-
nal Crohn’s disease or local injection for ﬁstulising
Crohn’s disease) in order to ameliorate both overall and
sustained response rates.
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Concomitant use of other drugs. Mesenchymal stromal
cells are used alongside with immunosuppressive drugs
in clinical studies, and they share common targets. Their
interaction should then be studied carefully. In vitro,
exposure of MSCs to physiological concentrations of aza-
thioprine, methotrexate, mercaptopurine and anti-TNFa
agents does not affect their survival and their inhibitory
capacities on peripheral blood mononuclear cell prolifer-
ation. There might even be an additive effect with mer-
captopurine and anti-TNFa antibodies.128 However, at
higher in vitro concentrations, azathioprine can decrease
the proliferation of rat bone marrow MSCs and increase
their apoptosis and necrosis.129 The inﬂuence of
immunosuppressive drugs on IFN-c secretion should
also be more carefully studied, since activation of MSCs
by IFN-c seems to be important for their action. In mur-
ine cardiac allograft, infusion of allogeneic MSCs in
combination with mycophenolate mofetil, which does
not affect IFN-c production by activated T cells, pro-
longed graft survival, while the combination of allogeneic
MSCs with CsA, which completely abrogates IFN-c pro-
duction by activated T cells, reduced their efﬁcacy.130, 131
Safety
No major MSC-related adverse event has been reported
so far, whether in clinical trials with patients suffering
from IBD, or in other diseases.132–138 A few studies have
shown mild and transient fever during or right after
injection, and this association was signiﬁcant in a meta-
analysis.138 No ectopic growth of tissues has been associ-
ated with local injections. Nevertheless, the apparent
absence of long-term engraftment might protect against
this risk, and a special attention should be paid to MSCs
that have been pre-treated with the aim of enhancing
their in vivo survival. Despite their immunosuppressive
properties, MSCs did not increase the risks of infection
or malignancy in clinical trials.138 Some animal studies
suggested that MSCs could promote tumour
growth,139, 140 or conversely have a tumour-suppressive
activity.141–143 These contradictory results could be
explained by a context-dependent role of MSCs in regu-
lating tumour growth.144, 145 In a small pilot human trial
in haematologic malignancies, co-transplantation of
MSCs and haematopoietic stem cells was apparently asso-
ciated with a higher relapse rate compared with control
(60% vs. 20%), but this has never been conﬁrmed by
other studies.146 In two studies using a murine model of
colitis-associated tumorigenesis induced by azoxymethane
and DSS, MSC therapy even resulted in a signiﬁcant sup-
pression of colitis-related neoplasm (reduction in tumour
numbers compared to controls), probably because of a
reduction of the inﬂammatory environment. A decreased
expression of pro-inﬂammatory cytokines and a down-
regulation of STAT3 phosphorylation have been impli-
cated,147 as well as an enhanced induction of Tregs from
naive T cells by MSC-secreted TGF-b.148 Clinical trials
with long-term follow-up should be performed to deﬁni-
tively assess the safety of MSC therapy.
CONCLUSIONS
Mesenchymal stromal cell therapy represents a hope for
the treatment of many dysimmune diseases. As they exert
both immunomodulatory effects and tissue repair promo-
tion, MSCs seem particularly promising in IBD, where a
dysregulated immune system causes tissue damages. Cur-
rently, the results of clinical trials are particularly encour-
aging in perianal ﬁstulising Crohn’s disease. Indeed, MSCs
have demonstrated their ability to heal perianal Crohn’s
disease ﬁstulae in patients refractory to conventional or
biologic therapy in several controlled trials. Moreover, for
ﬁstulising perianal Crohn’s disease, MSC therapy is a min-
imally invasive procedure that, unlike current surgical
options, does not injure the anal sphincter (and can even
promote a nonﬁbrotic healing of ﬁstulas). Unlike conven-
tional immunosuppressive drugs, it does not seem to
increase the risk of opportunist infections. MSCs still have
to demonstrate their efﬁcacy in luminal Crohn’s disease
and in ulcerative colitis. To address this issue, phase II and
III studies using both clinical remission and endoscopic
response as co-primary endpoints should be performed.
Furthermore, the optimal origin and sources of MSCs, as
well as dosage and modalities of administration, have still
to be determined. Future trials should aim to resolve these
questions in order to optimally use the great potential of
MSCs to treat IBD.
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